Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteonecrosis of the Jaw

From the College  |  Issue: September 2008  |  September 1, 2008

Osteonecrosis of the jaw (ONJ) is a condition in which an area of jawbone is not covered by the gums that has lasted for more than eight weeks. ONJ occurs when a facial bone begins to starve from a permanent or temporary lack of blood. As the name indicates—with osteo meaning bone and necrosis meaning death—the bone begins to die, causing pain and deterioration.

Risk factors for ONJ include older age, steroid use, diabetes, gum disease, and smoking. ONJ is also associated with radiation, infection, steroid use, and/or bisphosphonate therapy for cancer and/or osteoporosis. Although some risk factors have been identified, sometimes this condition can also occur spontaneously.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

ONJ resulting from bisphosphonate use may develop in patients after 18 to 22 months of therapy, but most cases it occurs after therapy that has been prolonged for more than five years. Why patients on bisphosphonates get ONJ is unknown; however, some feel it may be due to a decrease in blood vessel formation, a decrease in bone formation at the site, or toxic effects on the bone.

Some studies of osteoporosis patients on bisphosphonate therapy show that one in 100,000 to one in 263,158 get ONJ. According to patient–fact sheet writer Stuart Silverman MD, “because doses of IV bisphosphonates used to treat cancer can be ten times higher or more than the doses used for osteoporosis, cancer patients are more at risk for ONJ.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Many ONJ diagnoses stem from patients complaining of pain, which is often related to infection, soft tissue swelling, drainage, and exposed bone, and, according to Dr. Silverman, “Typically, the doctor or dentist makes the diagnosis when there is the presence of exposed bone lasting more than eight weeks.”

Most patients with ONJ should be treated conservatively with rinses, antibiotics, and pain medicines, and patients with periodontal disease should consider nonsurgical therapy before agreeing to surgical treatment.

A health program of oral hygiene and regular dental care is the optimal approach for lowering ONJ risk. Patients beginning bisphosphonate therapy and not receiving routine dental care should get a comprehensive oral exam as soon as possible. Any problems developing in the mouth should signal the need for dental review.

Download the complete fact sheet on osteonecrosis of the jaw as well as other patient-education materials at www.rheumatology.org by following the links to patient education from the Practice Support Menu.

Share: 

Filed under:ConditionsFrom the CollegeOsteoarthritis and Bone Disorders Tagged with:Diagnostic CriteriaONJOsteonecrosisPatient Fact Sheet

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

    Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

    December 12, 2022

    A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

    BlurryMe / shutterstock.com

    The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

    March 15, 2021

    Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences